Vaccines for neonatal viral infections: towards a live respiratory syncytial virus vaccine:a study in risk

E D McIntosh; F J Malinoski; V B Randolph

doi:10.1586/14760584.3.4.353

Vaccines for neonatal viral infections: towards a live respiratory syncytial virus vaccine:a study in risk

Expert Rev Vaccines. 2004 Aug;3(4):353-7. doi: 10.1586/14760584.3.4.353.

Authors

E D McIntosh¹, F J Malinoski, V B Randolph

Affiliation

¹ Wyeth, Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0HP, UK. mcintod@wyeth.com

PMID: 15270633
DOI: 10.1586/14760584.3.4.353

Abstract

There is risk attached to the development of respiratory syncytial virus vaccines, live attenuated or otherwise, but without the acceptance of this risk by manufacturers, health providers and the public, the conclusion of successful Phase III trials may lie in the distant future.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Humans
Infant, Newborn
Respiratory Syncytial Virus Infections / prevention & control*
Respiratory Syncytial Virus Vaccines / adverse effects
Respiratory Syncytial Virus Vaccines / immunology*
Respiratory Syncytial Viruses / genetics
Respiratory Syncytial Viruses / physiology
Vaccines, Synthetic / immunology

Substances

Respiratory Syncytial Virus Vaccines
Vaccines, Synthetic